With a 52 week trading range of $0.04 - $0.35 caveat emptor goes without saying. A sensible warning may not deter momentum riders and profit seekers with Plandai Biotechnology (PLPL), but maybe we'll find some readers that will share their due diligence: (1) why did Plandai go untraded? (2) revenues went to $0.00 in 2012 year-ending June 30th, what happened? (3) who are the company's largest shareholders? (3) $5.81 million in long term investments listed on the balance sheet, what is/are this and is that valuation reasonable? (4) it looks like about $3.5 million of new capital was raised (stock issuance), who bought? (5) the message was sent from someone at ragulp.com, who or what is ragulp? (6) prepared to take over the nutrition market, what does that mean? (7) the author of this report claims to be long PLPL but could also have turned a seller, and may short sell ... who is the author again? (8) what is Plandai's "production forecast for 2014 sales?" (9) where is this factory to be commissioned? (10) confusing, is it a $50 billion or $29 billion nutrition market?
Here's a full copy of the email.Yellow highlights at bottom added by editor for readers' reference.
More than 10 years have been invested into R&D and now Plandaí Biotechnology, Inc. (PLPL), a creator of highly bioavailablePhytofare™ plant extracts, is all set for commercialization.
201South Biscayne Boulevard, 28th Fl., Miami, Flor. 33131 USA